Erectile dysfunction medication would not only not aggravate certain coronary problems, but would also reduce cardiovascular risk.

Maduritos getting interesting.

Long before the Covid-19 pandemic and vaccine development procedures became a daily topic of conversation, Pfizer already had a ‘superstar’ drug in the pipeline: sildenafil, better known by its brand name Viagra. It is not, as is often argued, an aphrodisiac that can be consumed with pleasure: in 2018, the United Kingdom broke a record of 19 deaths related to this erectile dysfunction medication.

Medications for erection problems are based onPDE-5 inhibitor drugs, a treatment that has effects vasodilators. Because of the possible radical disturbances in blood circulation, it is not advised to men who have suffered a heart attack or other heart problems, as well as those with chronic kidney or liver problems.

Precisely for this reason, the health alerts on herbal products that promise to regain virility with ‘natural’ ingredients but actually hiding undeclared sildenafil are so delicate: It is precisely men with heart problems who are the most susceptible to seeking non-pharmacological alternatives, endangering their health in the process.

On the other hand, circulatory alterations linked to Viagra are related to striking neurosensory disorders, such as the deafness suffered by Hugh Hefner, owner of Playboy, or the ‘red vision’ of a young New Yorker. Against all these antecedents, a study by the Karolinska Institute of Sweden published in the Journal of the American College of Cardiology comes to change the story: patients with a stable coronary heart disease who take Viagra for impotence live longer and are less likely to have new attacks to the heart.

The appearance of erection problems, in fact, can be an indication that a male is suffering from cardiovascular disease. Local treatment may consist of alprostadil, a vasodilator that increases blood flow in the corpus cavernosum of the penis and promotes erection, or with the aforementioned PDE-5 inhibitors, which are taken as a pill before sex and inactivate the enzyme phosphodiesterase 5 (PDE-5).

With PDE-5 inhibited, there is a sudden drop in blood pressure that, as we have seen, helps with erection, but can have all kinds of consequences in the body. For this reason, it is not recommended for patients with coronary problems for fear of an increased risk of heart attack. However, in 2017, Dr. Martin Holzmann’s team showed that men who took Viagra despite having suffered a cardiovascular accident not only did they tolerate it well, but they lived longer and in better health.

For their next study, the researchers set out to compare the effects of alprostadil versus those of PDE-5 inhibitors in patients who had suffered from heart attack, balloon angioplasty, or heart surgery bypass coronary at least six months before starting erectile dysfunction treatment. “The risk of a new cardiovascular accident is higher during the first six months, after which we consider the disease stable,” explains Holzmann.

After collecting data from 16,500 men treated with PDE-5 inhibitors and 2,000 with alprostadil, the researchers found that patients in the first group lived longer and were less likely to end up with new heart problems and / or interventions. TO the greater the frequency of taking Viagra, in fact, the greater the risk reduction.

“Potency problems are common in older men,” recalls Holzmann. Although the causal relationship between taking Viagra and improved cardiovascular health compared to other drugs has not been established in this study, the specialist hopes that these cardioprotective effects encourage patients to seek medical treatment.